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ABSTRACT
Background: Approximately 68 brands of azithromycin capsule formulations
re available in Pakistan; however, published data on their bioequivalence in the
akistani population are not available.
Objective: Upon instructions from and approval of the Ministry of Health,
Pakistan, this study was designed to evaluate the bioequivalence of a locally manu-
factured azithromycin capsule formulation with a reference formulation from a
multinational manufacturer. This study compared dissolution profiles, relative bio-
availability, and other pharmacokinetic parameters of the 2 formulations.
Methods: A single oral 500-mg dose of the 2 formulations was administered to
12 healthy adult Pakistani male volunteers under fasting conditions in a randomized,
open-label, 2-period crossover study. The trial included collection of blood samples
over 48 hours and a 2-week washout period. Azithromycin serum concentrations were
quantified using a validated RP-HPLC/ultraviolet (UV) detection method. These
results were used to determine the intended pharmacokinetic parameters. As man-
dated by the US Food and Drug Administration and the European Medicine Agency,
the test and reference formulations were considered bioequivalent if the 90% CIs of
the geometric mean ratios for the log-transformed values of their pharmacokinetic
parameters were within the predetermined range of 0.8 to 1.25.
Results: When subjected to a simple model independent approach of disso-
ution profile comparison, f1 (difference) and f2 (similarity factor) were found to be
.47 and 70.04, respectively. Similarly, the 2 azithromycin capsule formulations were
ell tolerated by all volunteers. Low %CV of the pharmacokinetic parameters at a
ample size of 12 and significance level of 0.05 contributed to acceptable (0.8)
ower of the test. The 90% CIs for the ratios of Cmax, AUC0–48, Tmax, t1/2, and mean
residence time, respectively, were 0.83–0.93, 0.85–1.10, 0.86–1.08, 0.92–1.17, and
0.92–1.16.
Conclusion: This single-dose study found that test and reference formulations
met the regulatory criteria for bioequivalence in these fasted, healthy male Pakistani
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INTRODUCTION
Azithromycin, the prototype of the azalide subclass of macrolides,1 has certain
haracteristics, including greater acid stability, which may enable superior absorp-
ion,2,3 greater tissue penetration, and a significantly longer t1/2, enabling once-daily
osing.2,4,5 It exhibits antibacterial activity against a number of gram-positive
organisms, such as Staphylococcus aureus, Streptococcus agalactiae, Str. pyogenes, and Str.
Pneumoniae, and gram-negative Haemophilus influenzae, Moraxella catarrhalis, and Chla-
mydia trachomatis.6
Bioequivalence is a term used in pharmacokinetics that describes the expected in
ivo biological equivalence of 2 proprietary preparations of a drug. The US Food and
rug Administration (FDA) defines bioequivalence as “the absence of a significant
ifference in the rate and extent to which the active ingredient(s) in pharmaceu-
ical equivalents or pharmaceutical alternatives become(s) available at the site of
rug action when administered at the same molar dose under similar conditions
n an appropriately designed study.”7 The need for bioequivalence studies became
pparent after reports of digoxin,8 triamterene,9 and phenytoin10 toxicities re-
sulting from minor changes in their formulations. Several approaches are consid-
ered for conducting bioequivalence studies, including both in vivo and in vitro
methods; however, the pharmacokinetic approach is the most commonly used
method. The reason might be that the primary aim of bioequivalence studies is
to assess the rate and extent of drug absorption, which can be readily assessed by
key pharmacokinetic parameters such as Cmax, Tmax, AUC, mean residence time
(MRT), area under moment curve (AUMC), and t1/2.
11,12
In Pakistan, most pharmaceutical products are manufactured at local pharma-
eutical companies. These products are significantly more economical than that of
ultinational competitors. Local manufacturers may adversely modify a formu-
ation by incorporating low-grade, less-expensive excipients to reduce production
osts without affecting profit. Approximately 68 brands of azithromycin capsule
ormulations are available in Pakistan13; however, published data regarding their
bioequivalence in the Pakistani population are not available. This study was
designed, upon the instructions and approval of the Ministry of Health (MoH),
Pakistan, to compare the bioequivalence of an azithromycin capsule formulation
manufactured locally in the Khyber Pakhtunkhwa province with that of a
reference formulation from a multinational manufacturer. This study compared
their relative bioavailability and other pharmacokinetic parameters as recom-
mended by the US FDA14 and the European Medicine Agency15 (EMEA) in
healthy male Pakistani volunteers.
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Formulations
The reference formulation* and the test formulation† of azithromycin were
250-mg capsules. Of the 68 brands of the azithromycin capsule formulations available
in Pakistan, only 5 are manufactured in the Khyber Pakhtunkhwa province. Thus, the
test formulation was randomly selected from these 5 brands using a computer-based
random number table after assigning them numbers from 1 to 5.
Assay and In Vitro Dissolution Studies
Five hundred capsules (50 strips) of the specified batches of the formulations were
urchased locally, and the strips were numbered from 1 to 50. Out of the 50 strips,
0 strips were randomly selected using a computer-generated, random sample table.
ne capsule from each strip was selected and assayed for the active ingredient using
he reversed phase high-performance liquid chromatography/ultraviolet (RP-HPLC/
V) detection method.
To evaluate the pharmaceutical equivalence of the test and reference products,
issolution test was performed using the US Pharmacopeia (USP) dissolution appa-
atus-II, paddle method according to the official monograph.16 Samples collected at
various time intervals were analyzed using the RP-HPLC/UV detection method
described later, and a simple model independent approach using the difference factor
(f1) and the similarity factor (f2) was adopted to compare dissolution profiles. The f1
calculates the percent difference between the 2 curves at each time point and is the
measure of the relative error between the 2 curves, whereas the f2 is a logarithmic
reciprocal square root transformation of the sum of squared error and is the measure
of the similarity in the percent of dissolution between the 2 curves. These factors were
calculated using the following equations, respectively17,18:
f1t1n Rt Ttt1n Rt 100
here n is the number of time points, Rt is the dissolution value of the reference
roduct at time t, and Tt is the dissolution value of the test product at time t.
f2 50 log1 	 1m
j1m wjRt Tt2
0.5
 100
where m is any time point and wj is an optional weight factor.
The specific procedure used to determine f1 and f2 began with determining the
issolution profile of the products (12 units each). The same procedure was adopted
or the selection of the capsules as specified for the assay; however, 12 strips were
*Trademark: Azomax (Novartis Pharma [Pakistan] Ltd, Karachi, Pakistan). Batch number J0003, expiration
05/2011.†Trademark: Ezill (Dr. Raza Pharma Pvt Ltd, Peshawar, Pakistan). Batch number 295, expiration 09/2011.
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at each time interval, f1 and f2 were calculated using the aforementioned equations.
or curves to be considered similar, f1 values should be close to 0, and f2 values should
be close to 100. Generally, f1 values up to 15 (0–15) and f2 values 50 (50–100)
ensure sameness or equivalence of the 2 curves and, thus, of the performance of the
2 products.17,18
Volunteers
This study was conducted according to the principles of the Declaration of
elsinki and its amendments.19 The study protocol was approved by the Ethical
Committee of the Department of Pharmacy, University of Peshawar, Pakistan. The
study objectives and the effects of drugs used in the study were explained to
volunteers at the start of the study, and informed consent was obtained. Study
volunteers were also compensated financially.
Healthy adult male volunteers (students of the Department of Pharmacy, Univer-
sity of Peshawar, Pakistan) aged 18 years were recruited for this study using the
convenience sampling (sometimes known as grab or opportunity sampling) approach,
a nonprobability sampling that involves the sample being drawn from the part of the
population that is close at hand. A detailed medical history was obtained and a
clinical examination was performed for all volunteers at the beginning of the study
under the supervision of a qualified physician. In addition, 12-lead electrocardiogra-
phy, complete blood count, blood pressure, blood sugar level, liver function tests,
lipid profile, and renal function tests were also carried out in all study volunteers.
Persons with any systemic pathology such as diabetes mellitus; gastrointestinal,
renal, hepatic, or cardiovascular disease; or recent surgery were not eligible for the
study. Persons with abnormal clinical laboratory test values were also excluded.
Similarly, persons with a history of allergic responses to any class of drugs were
excluded from the study. Volunteers were prohibited from participation if they took
any medicines or followed nonstandard diets at least 2 weeks before the start of the
trial. An initial group of 16 healthy male volunteers were selected after providing
informed consent. Each gave a medical history and underwent clinical examination
and biochemical investigations. Four volunteers showed high liver function test
values and were excluded from the study. The remaining 12 volunteers met all
Table I. Demographic characteristics for volunteers enrolled in the study. Data are given
as mean (SD); range.
No. of Subjects
Demographic Characteristics
Age, y Weight, kg Height, in
12 25 (4); 20–30 66 (8); 55–74 65 (3); 61–69inclusion criteria. Demographic characteristics are shown in Table I.
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Samiullah et al.Study Design and Drug Administration
Various bioequivalence parameters of the 2 products were assessed under fasting
onditions in a randomized, open-labeled, balanced, 2-period, 2-treatment, 2-se-
uence, single-dose, crossover study with a 2-week washout period at the Department
f Pharmacy, University of Peshawar, Pakistan.
Using a computer-based random number table, volunteers were randomly divided
nto 2 groups (group 1 and group 2), each consisting of 6 patients. During the first
tudy period, patients in group 1 received a single oral 500-mg dose of the reference
ormulation, whereas patients from group 2 received the test formulation. In the
econd study period, the order was reversed. The scheme of the studies for the
espective drugs is summarized in Table II. A nonblind approach was applied; both
olunteers and investigators were aware of the formulations given to each group. For
harmacokinetic studies, capsules were also randomly selected using the same pro-
edure as specified for the dissolution studies; however, 2 capsules were taken from
ach strip in this case.
All volunteers fasted for 8 hours before administration of the dose with 200 mL of
ater. They were not permitted to take any food for another 4 hours after ingestion
f the dose; however, they ate a uniform breakfast, lunch, and dinner 4, 8, and 12
ours after drug administration, respectively.
Tolerability Assessment
Tolerability in volunteers was assessed before medication administration and every
hours during the study through physical examination, monitoring vital signs
temperature, blood pressure, heart rate, and respiratory rate) and interviewing them
bout adverse events that may be associated with the use of azithromycin (eg,
Table II. Study design for the bioequivalence evaluation of test* and reference† azithro-
mycin capsule formulations.
Study Period Group Azithromycin Formulation Administered
First 1 Two capsules (500-mg dose) of azithromycin
reference formulation
2 Two capsules (500-mg dose) of azithromycin
test formulation
2-Week wash-out period
Second 1 Two capsules (500-mg dose) of azithromycin
test formulation
2 Two capsules (500-mg dose) of azithromycin
reference formulation
*Trademark: Ezill (Dr. Raza Pharma Pvt Ltd, Peshawar, Pakistan). Batch number 295, expiration 09/
2011.
†Trademark: Azomax (Novartis Pharma [Pakistan] Ltd, Karachi, Pakistan). Batch number J0003, expira-
tion 05/2011.eadache, nausea, vomiting, abdominal cramps/pain, loose and/or bloody stools,
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Current Therapeutic Researchallergic reactions, hearing problems, eye or vision problems, speaking and swallowing
problems, and muscular weakness) under the supervision of a qualified physician.
Sample Collection and Processing
Venous blood samples (5 mL) were collected at 0 hour (ie, just before dosing) and
t 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours following the administration of
zithromycin capsules in gel and clot-activator tubes. After clotting, the serum was
eparated from the blood by centrifugation at 5000 rpm for 10 minutes at 0°C and
tored at –80°C until analysis.
Analysis of Samples
Samples were analyzed by a validated RP-HPLC/UV detection method, discussed
elow.
Azithromycin standard was provided by Saydon Pharmaceuticals Pvt Ltd, Pesha-
ar, Pakistan and roxithromycin was provided by Bryon Pharmaceuticals Pvt Ltd,
eshawar, Pakistan. HPLC-grade solvents such as triethylamine, acetonitrile, diethyl
ther, and methanol and all other chemicals and reagents such as sodium hydroxide
NaOH) and potassium dihydrogen phosphate were purchased from Sigma-Aldrich
Oslo, Norway). Ultrapure water was prepared using a Millipore ultrapure water
ystem (Billerica, Massachusetts). All these reagents and chemicals were used without
urther purification.
To prepare azithromycin and roxithromycin (internal standard) stock solutions,
eighed amounts of each were dissolved in acetonitrile. Internal standard solution (to
ive a final concentration of 1.0 g/mL), to be added to all standard solutions and
erum samples, was then prepared by dilution of the corresponding stock solution
ith acetonitrile. Similarly, standard solutions of azithromycin in the range of 0.02
o 2.0 g/mL (11 concentration levels), each containing 1.0 g/mL of internal
standard solution, were also prepared by dilution of the azithromycin stock solution.
Similarly, standard solution containing 1.0 g/mL each of azithromycin and internal
tandard (1:1 mixtures) was also prepared.
Liquid–liquid extraction was adopted for the sample preparation. At the time of
nalysis, the samples were thawed at room temperature and roxithromycin solution (1
g/mL) used as the internal standard was vertex-mixed with 500 L sample. These
samples were then extracted with diethyl ether (3  5 mL). The organic layer was
evaporated at approximately 60°C under a steam of nitrogen gas, the residues were
dissolved again in mobile phase (500 L), and 20 L samples injected into the HPLC
ystem.
Chromatographic separation of the samples was carried out on a Perkin Elmer
Norwalk, Connecticut) HPLC system equipped with a Series 200 pump, vacuum
egasser, Peltier column oven, and UV-Vis detector and Rheodyne 7725i manual
njector. The data were then analyzed on Perkin Elmer Totalchrom chromatography
orkstation (version 6.3.1.), interfaced with the HPLC hardware through network
hromatography interface (NCI) 900. Analytes were separated using Kromasil 100
P18 (250  4.6 mm, 5 m; Thames Restek, Saunderton, United Kingdom)
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Samiullah et al.analytical column protected by a Bondapak RP18 (30  4.6 mm, 10 m; Merck
kGaA, Darmstadt, Germany) precolumn guard cartridge.
Analyses were performed at ambient temperature using acetonitrile-50 mM po-
tassium dihydrogen phosphate buffer pH 7.00 (60:40 v/v) containing triethylamine
(0.6 mL/L) as isocratic mobile phase pumped at a flow rate of 1.5 mL/min. The
injection volume was kept at 20 L, and the eluents were monitored at 205 nm. As
noted, roxithromycin (at the level of 1.0 g/mL) was used as the internal standard.
The chromatographic method was validated according to international guidelines,
with emphasis on linearity within the expected concentration range, sensitivity,
recovery, and precision.20
Sample concentrations, C, were calculated using the following formula:
C ASampleAnalyte ⁄ ASampleIS  ACSIS ⁄ ACSAnalyte CCS FD
where ASample
Analyte and ACS
Analyte are peak areas of the analyte in serum samples and 1:1
mixture, respectively; ASample
IS and ACS
IS are peak areas of the internal standard in serum
samples and 1:1 mixture, respectively; CCS is the concentration of analyte in the 1:1
ixture; and FD is the dilution factor.
Pharmacokinetics and Statistical Analyses
Serum concentrations of azithromycin at various time intervals following oral
dministration of the 2 products were determined for each volunteer and mean values
ere calculated. A noncompartment model, as proposed by Shargel and Yu,12 was
used to access the following pharmacokinetic parameters: Cmax, Tmax, AUC0–t,
AUMC, MRT, and t1/2. Cmax and Tmax were obtained directly from the concentra-
ion–time curve; AUC0–t was calculated using the linear trapezoidal method, and
UMC and MRT were also calculated using same data. Elimination rate constant (ke)
as calculated by applying a log-linear regression analysis to at least the last 3
uantifiable azithromycin concentrations, and then t1/2 was calculated as 0.693/ke.
12
All of these pharmacokinetic parameters were determined using the statistical pack-
age PK Solutions 2.0 (SummitPK, Montrose, Colorado).
Pharmacokinetic data for the 2 formulations were log-transformed before statistical
analysis, which was based on the 90% CIs for the ratio of the geometric means for
these log-transformed pharmacokinetic parameters of the 2 formulations (test/refer-
ence). If the 90% CIs for the ratios of Tmax, Cmax, and AUC0–48 values of the test and
reference formulations fell within the range of 0.8 to 1.25, then these were considered
bioequivalent, as recommended by the US FDA14 and the EMEA.15 The lower
boundary (LB) and higher boundary (HB) of 90% CIs were calculated using the
following equations21:
LB eMDtvalueSD⁄n 
HB eMDtvalueSD⁄n 
where MD is the mean difference and SD refers to the standard deviation of the transformed
metric; n is the number of patients in the study; and t-value is 1.7959 for 12 patients.
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Current Therapeutic ResearchThe unpaired, or independent, samples t test was taken into account to test the null
ypothesis of the bioequivalence at the 0.05 significance level using the statistical
ackage Minitab 15.0 (Minitab Inc, State College, Pennsylvania). In addition to the
ppropriate 90% CIs for the comparison of the 2 formulations, summary statistics
uch as median, range (minimum and maximum values), and %CV were also
alculated for pharmacokinetic parameters of interest.
RESULTS
Assay and In vitro Dissolution Studies
The mean (SD) percentage of the active ingredient in the test and reference
ormulations was found to be 99% (2%) and 98% (1%), respectively.
Azithromycin mean in vitro drug release (dissolution) profiles of the test and reference
apsule formulations were determined (Figure 1), and the data were subjected to a simple
odel independent approach of dissolution profile comparison. The f1 and the f2 were
found to be 5.47 and 70.04, respectively (Table III).
Tolerability
Both test and reference azithromycin capsule formulations were well tolerated by all
atients in this study. No unexpected incidents occurred that influenced study outcomes,
nd all volunteers continued to study end and were discharged in good health.
Validation of the Analytical Method
The HPLC method developed for the quantification of azithromycin was linear in the
ange of 0.02 to 2g/mL. The correlation coefficients (r2) of all standard curves were more
than 0.997 for serum samples (Figure 2). The lower limit of quantification was 20 ng/mL,
and limit of detection was 5 ng/mL for azithromycin in serum. The mean percent recovery
Figure 1. Azithromycin in vitro drug release profile of test () and reference (●) formula-
tions. Each point represents mean (SD) of 12 capsules.(n  5 [where n is the number of samples tested]) was found to be 97% at the 2
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Samiullah et al.nominal concentration levels. Results of the analysis repeatability and intermediate
precision (intraday and interday reproducibility) reveal complete harmony among the
repeated analyses and intraday and interday studies, as shown in Table IV.
Pharmacokinetics and Statistical Analyses
Azithromycin mean plasma concentration–time profiles after administration of
he test and reference formulations in twelve Pakistani healthy volunteers are
hown in Figure 3. Mean (SD) values of various pharmacokinetic parameters for
Figure 2. Calibration curve for azithromycin spiked in serum samples (y  0.097x 
Table III. Comparison of the dissolution profile of 2 azithromycin capsule formulations
(n  12, where n is the number of capsules tested of each formulation).
Time (min)
Mean % Release
Difference
Factor (f1)
Similarity
Factor (f2)
Test
Formulation
Reference
Formulation
0 0 5.47 70.04
5 39 43
0 56.6 61
5 76 79
f1 calculates the percent (%) difference between the 2 curves at each time point and is the measure of
he relative error between the 2 curves; f2 is a logarithmic reciprocal square root transformation of the
um of squared error and is the measure of the similarity in the percent (%) dissolution between the 2
urves.0.008; r2  0.997 [as in Table IV]). Each point is a mean of triplicate injections.
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Current Therapeutic Researchthe test and reference formulations, respectively, were Cmax, 0.34 (0.03) and 0.38
0.04) g/mL; AUC0-48, 2.75 (0.46) and 2.85 (0.48) g·h/mL; AUMC, 36.90
11.02) and 36.57 (9.14) g·h/mL; t1/2, 9.20 (1.63) and 8.79 (1.02) h; Tmax, 2.83
(0.39) and 2.91 (0.29) h; MRT, 13.27 (2.35) and 12.68 (1.48) h. Similarly, the
90% CIs for the ratios of Cmax, AUC0 – 48, Tmax, MRT, and t1/2 for the 2
formulations, respectively, were 0.83– 0.93, 0.85–1.10, 0.92–1.17, 0.86 –1.08,
0.85–1.1, and 0.92–1.16, which, along with summary statistics such as median,
range, and %CV, are given in Table V.
DISCUSSION
Aspects of this study design, such as use of a single dose; recruitment of healthy
Table IV. Recovery, precision, sensitivity, calibration range, and linearity of the developed
method.
Validation Parameters
Azithromycin
Mean (SD); %RSD*
ecovery
0.5 g/mL† 97 (1.58)‡; 1.63
1.0 g/mL† 98.4 (0.98)‡; 0.98
Precision
Repeatability
Analysis repeatability
0.5 g/mL§ 0.491 (0.005); 0.94
Intermediate precision
Intra-day reproducibility
0.25 g/mL¶ 0.247 (0.002); 1.17
0.5 g/mL¶ 0.495 (0.005); 1.01
Inter-days reproducibility
0.25 g/mL¶ 0.245 (0.005; 2.04
0.5 g/mL¶ 0.491 (0.008); 1.55
ensitivity
Lower limit of quantification 20 ng/mL
Limit of detection 5 ng/mL
alibration range 0.02–2 g/mL
Linearity y  0.097x  0.008, r2  0.997
Percent (%) residual SD.
†n  5.
‡percent (%) of recovery.
§n  10.
quantity recovered in g/mL.
¶n  3.volunteers from the Department of Pharmacy, University of Peshawar, Pakistan;
104
ta
a
m
w
(
s
o
v
e
Samiullah et al.fasting; and standardized meals limit generalizability of these results beyond the
population studied and the study conditions; however, these were consistent with
the regulatory guidelines14,15 to bring uniformity in the testing conditions for
he 2 formulations.
Azithromycin was measurable from the second sampling time (0.5 hour) in
lmost all volunteers, assuming that both capsule formulations were readily
bsorbed from the gastrointestinal tract. All the calculated values for the phar-
acokinetic parameters such as Cmax, Tmax, AUC0 – 48, AUMC, t1/2, and MRT
ere well within the range of previously reported values.22–28 Low variability
%CV) of the pharmacokinetic parameters Cmax, Tmax, and AUC0 – 48 at sample
ize of 12 and significance level of 0.05 contributed to acceptable (0.8) power
f the test. The mean values for Cmax, Tmax, AUC0 – 48, AUMC, MRT, and t1/2 of
the 2 formulations did not differ significantly (P  0.05), suggesting that the
serum profiles generated by the test formulation were not significantly different
from those produced by the reference formulation.
The 90% CIs for the ratios of various pharmacokinetic parameters for the test
and reference formulations were within the acceptable interval of 0.8 –1.25
proposed by the regulatory authorities for bioequivalence.14,15 Similarly, the in
itro dissolution studies found that the formulations were pharmaceutically
quivalent with respect to dosage form.
CONCLUSIONS
This single-dose study found that the test and reference azithromycin formula-
tions met regulatory criteria for bioequivalence in the fasting healthy Pakistani
Figure 3. Serum concentration versus time profile of azithromycin after 500-mg oral
dose of test () and reference (●) formulations. Each point represents mean
(SD).male volunteers in this study. No statistically significant differences were found
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pharmacokinetic parameters. The 90% CIs for the ratios of various pharmacoki-
netic parameters were also found to be within the proposed acceptance limits for
bioequivalence. It was concluded, therefore, that the 2 azithromycin capsule
Table V. Pharmacokinetic parameters and 90% CIs* for the ratios of the geometric means
of their log-transformed values for the 2 azithromycin capsule formulations (n 
12, where n is the number of volunteers).
Pharmacokinetic
Parameters
Test
Formulation
Reference
Formulation P
T/R Point
Estimate
Cmax (g/mL )
Mean (SD) 0.34 (0.03) 0.38 (0.04) 0.06 0.88
Range 0.31–0.40 0.31–0.47 0.83–0.93*
Median 0.34 0.39
%CV 8.99 14.21
max (h)
Mean (SD) 2.83 (0.39) 2.91 (0.29) 0.56 0.97
Range 2.00–3.00 2.00–3.00 0.86–1.08*
Median 3.00 3.00
%CV 13.74 9.90
UC0–48 (h·g/
mL)
Mean (SD) 2.75 (0.46) 2.85 (0.48) 0.61 0.96
Range 2.00–3.76 2.14–3.55 0.85–1.10*
Median 2.72 2.87
%CV 16.74 16.26
t1/2 (h)
Mean (SD) 9.20 (1.63) 8.79 (1.02) 0.47 1.05
Range 5.96–12.03 6.83–10.70 0.92–1.17*
Median 8.70 8.81
RT (h)
Mean (SD) 13.27 (2.35) 12.68 (1.48) 0.47 1.05
Range 8.60–17.35 9.85–15.5 0.92–1.16*
Median 12.55 12.70
UMC (h·g/mL)
Mean (SD) 36.90 (11.02) 36.57 (9.14) 0.94 –
Range 23.98–61.34 21.08–50.82 –
Median 33.31 36.76
AUMC  area under moment curve; CV  coefficient of variation; MRT  mean residence time; T/R 
test/reference.formulations may be prescribed interchangeably.
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